Please ensure Javascript is enabled for purposes of website accessibility

Gilead Sciences Stops Accepting Emergency-Use Applications for Remdesivir

By Cory Renauer - Mar 23, 2020 at 1:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A flood of compassionate-use requests from COVID-19 patients seeking to try the experimental antiviral drug has overwhelmed the approval system.

The coronavirus pandemic has overtaxed an expanded-use system that just wasn't designed to handle the volume of requests it's getting right now for remdesivir, an experimental antiviral treatment from Gilead Sciences (GILD 0.16%).

The overwhelming surge in demand has forced the company to stop accepting new requests from individuals with COVID-19 who want to try the treatment.

Hand halting a coronavirus.

Image source: Getty Images.

The FDA can allow the use of an experimental treatment in cases when patients aren't eligible to enter an ongoing clinical trial of the drug in question. But getting permission to try such an unproven treatment is an involved process that requires consent from an informed patient and lots of paperwork from their physician and Gilead Sciences just to get started.

Given that no treatments have yet been proven to be effective against SARS-CoV-2 in proper clinical trials, there's enormous interest in those that appear promising, which remdesivir does.

So Gilead Sciences has been meeting as many of these requests for use of remdesivir as possible, but they have piled up beyond the system's ability to process. For each request, an investigational review board (IRB) needs to review the physician's treatment plan and ensure the patient knows what they're getting into. If the IRB approval on an individual application, it still needs to be reviewed and approved by the FDA before treatment can begin.

In recent weeks, the number of individual requests for permission to use remdesivir has grown so rapidly that Gilead Sciences now expects it will have pivotal trial data in hand -- and possibly an FDA approval for the drug as a COVID-19 treatment -- before the IRB and FDA can work through the current backlog of expanded-use applications. 

In late February, Gilead Sciences began a pair of phase 3 clinical trials in the U.S. to measure the safety and efficacy of remdesivir in adults with COVID-19. There are also trials underway in China's Hubei province that could provide results in April.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.83 (0.16%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.